Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 100%

Published: 2026-08-19

Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 100%
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.

Originally sourced from cnbc

Read the full story on Global Insight Daily